Chien-Kuo Wang

Dr. Chien-Kuo Wang

Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMing-Tsung Chuang
Ming-Tsung Chuang
YLYi-Sheng Liu
Yi-Sheng Liu
YTYi-Shan Tsai
Yi-Shan Tsai
YCYing-Chen Chen
Ying-Chen Chen
Chien-Kuo WangChien-Kuo Wang
Chien-Kuo Wang
This meta-analysis examined roles of several metabolites in differentiating recurrent tumor from necrosis in patients with brain tumors using MR perfusion and spectroscopy. Medline, Cochrane, EMBASE, and Google Scholar were searched for studies using perfusion MRI and/or MR spectroscopy published up to March 4, 2015 which differentiated between recurrent tumor vs. necrosis in patients with primary brain tumors or brain metastasis. Only two-armed, prospective or retrospective studies were included. A meta-analysis was performed on the difference in relative cerebral blood volume (rCBV), ratios of choline/creatine (Cho/Cr) and/or choline/N-acetyl aspartate (Cho/NAA) between participants undergoing MRI evaluation. A χ2-based test of homogeneity was performed using Cochran’s Q statistic and I2. Of 397 patients in 13 studies who were analyzed, the majority had tumor recurrence. As there was evidence of heterogeneity among 10 of the studies which used rCBV for evaluation (Q statistic = 31.634, I2 = 97.11%, P < 0.0001) a random-effects analysis was applied. The pooled difference in means (2.18, 95%CI = 0.85 to 3.50) indicated that the average rCBV in a contrast-enhancing lesion was significantly higher in tumor recurrence compared with radiation injury (P = 0.001). Based on a fixed-effect model of analysis encompassing the six studies which used Cho/Cr ratios for evaluation (Q statistic = 8.388, I2 = 40.39%, P = 0.137), the pooled difference in means (0.77, 95%CI = 0.57 to 0.98) of the average Cho/Cr ratio was significantly higher in tumor recurrence than in tumor necrosis (P = 0.001). There was significant difference in ratios of Cho to NAA between recurrent tumor and necrosis (1.02, 95%CI = 0.03 to 2.00, P = 0.044). MR spectroscopy and MR perfusion using Cho/NAA and Cho/Cr ratios and rCBV may increase the accuracy of differentiating necrosis from recurrent tumor in patients with primary brain tumors or metastases.

1 August 2004 in Radiology
Verified
Journal Article
Closed access
Chien-Kuo WangChien-Kuo Wang
Chien-Kuo Wang
CLChun-Wei Li
Chun-Wei Li
THTsyh-Jyi Hsieh
Tsyh-Jyi Hsieh
SCSang-Hsiung Chien
Sang-Hsiung Chien
GLGin-Chung Liu
Gin-Chung Liu
KTKun-Bow Tsai
Kun-Bow Tsai
To determine if in vivo detection of choline by using hydrogen 1 (1H) magnetic resonance (MR) spectroscopy with dynamic contrast material-enhanced MR imaging can help differentiate between benign and malignant musculoskeletal tumors. MR imaging was performed in 36 consecutive patients with bone and soft-tissue tumors larger than 1.5 cm in diameter. Examinations were performed at 1.5 T with a surface coil appropriate for the location of the lesions. Single-voxel 1H MR spectroscopy was performed by using a point-resolved spectroscopic sequence with echo times of 40, 135, and 270 msec. The volume of interest within lesions was positioned on the areas of early enhancement (<8 seconds after arterial enhancement) according to the findings of dynamic contrast-enhanced MR imaging with subtraction. The criterion for determining whether choline was present in a lesion was a clearly identifiable peak at 3.2 ppm in at least two of the three spectra acquired at echo times. MR spectroscopic results and histopathologic findings were determined in blinded fashion and compared with kappa statistics. P <.001 was considered to indicate a significant difference. Choline was detected in 18 of 19 patients with malignant tumors and in three of 17 patients with benign lesions. The three benign lesions included one perineurioma, one giant cell tumor, and one abscess. Choline was not detected in 14 patients with benign lesions nor in one patient with a densely ossifying low-grade parosteal osteosarcoma. In vivo 1H MR spectroscopy characterized bone and soft-tissue tumors, resulting in a sensitivity of 95%, specificity of 82%, and accuracy of 89% (P <.001). Choline can be reliably detected in large malignant bone and soft-tissue tumors by using a multiecho point-resolved spectroscopic protocol. 1H MR spectroscopy can help differentiate malignant from benign musculoskeletal tumors by revealing the presence or absence of water-soluble choline metabolites.

2 December 2021 in European Radiology
Verified
Journal Article
Closed access
PDF file
LHLi-Ting Huang
Li-Ting Huang
YTYi-Shan Tsai
Yi-Shan Tsai
CLCheng-Fu Liou
Cheng-Fu Liou
TLTsung-Han Lee
Tsung-Han Lee
PKPo-Tsun Paul Kuo
Po-Tsun Paul Kuo
Chien-Kuo WangChien-Kuo Wang
Chien-Kuo Wang

3 August 2018 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YLYi-Sheng Liu
Yi-Sheng Liu
CLChia-Ying Lin
Chia-Ying Lin
MCMing-Tsung Chuang
Ming-Tsung Chuang
YTYi-Shan Tsai
Yi-Shan Tsai
Chien-Kuo WangChien-Kuo Wang
Chien-Kuo Wang
MOMing-Ching Ou
Ming-Ching Ou
Currently, no standard of care or therapies have been established for patients with advanced HCC. We evaluated the efficacy and safety of conventional transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin (cTACE) and TACE with doxorubicin-loaded drug eluting beads (DEB-TACE). This retrospective study included 273 patients who received cTACE (n = 201) or DEB-TACE. Tumor response, survival, and adverse events were evaluated over a 5-year follow-up period. During 5-year follow-up, a greater percentage of patients treated with cTACE died than those treated with DEB-TACE (76.1% vs. 66.7%) (P = 0.045). At the last evaluation, all surviving patients had disease progression and no differences were seen between treatment groups. However, the time to disease progression differed between groups; median time to disease progression was 11.0 months for cTACE and 16.0 months for DEB-TACE (P = 0.019). The median survival time was 37 months in both treatment groups. No significant differences were observed between cTACE and DEB-TACE therapies in subgroups of patients with BCLC stage A or stage B + C either in survival time or time to disease progression (P values > 0.05). No significant differences were observed in survival status or disease progression between cTACE and DEB-TACE in patient subgroups with either tumor number > 5 or with the sum of the diameter of largest five HCC tumors being > 7 cm. DEB-TACE demonstrates greater long-term benefits than cTACE in treating treatment-naïve patients with HCC. Results of this long-term study support the use of DEB-TACE in treating HCC.

30 April 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
CYChing-Juei Yang
Ching-Juei Yang
YHYi-Hung Huang
Yi-Hung Huang
Chien-Kuo WangChien-Kuo Wang
Chien-Kuo Wang
JWJing-Yao Wang
Jing-Yao Wang
CCChih-Chia Chen
Chih-Chia Chen
YFYu-Hua Dean Fang
Yu-Hua Dean Fang
In this study, we modified the previously proposed X2CT-GAN to build a 2Dto3D-GAN of the spine. This study also incorporated the radiologist’s perspective in the adjustment of input signals to prove the feasibility of the automatic production of three-dimensional (3D) structures of the spine from simulated bi-planar two-dimensional (2D) X-ray images. Data from 1012 computed tomography (CT) studies of 984 patients were retrospectively collected. We tested this model under different dataset sizes (333, 666, and 1012) with different bone signal conditions to observe the training performance. A 10-fold cross-validation and five metrics—Dice similarity coefficient (DSC) value, Jaccard similarity coefficient (JSC), overlap volume (OV), and structural similarity index (SSIM)—were applied for model evaluation. The optimal mean values for DSC, JSC, OV, SSIM_anteroposterior (AP), and SSIM_Lateral (Lat) were 0.8192, 0.6984, 0.8624, 0.9261, and 0.9242, respectively. There was a significant improvement in the training performance under empirically enhanced bone signal conditions and with increasing training dataset sizes. These results demonstrate the potential of the clinical implantation of GAN for automatic production of 3D spine images from 2D images. This prototype model can serve as a foundation in future studies applying transfer learning for the development of advanced medical diagnostic techniques.

1 March 2013 in European Journal of Radiology
Verified
Journal Article
Closed access
CCChia-Hui Chen
Chia-Hui Chen
YLYi-Sheng Liu
Yi-Sheng Liu
PCPei-Hsi Chou
Pei-Hsi Chou
CHChin-Chiang Hsieh
Chin-Chiang Hsieh
Chien-Kuo WangChien-Kuo Wang
Chien-Kuo Wang